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A commentary by Andrew J. Schoenfeld,
MD, MSc, is linked to the online version of
this article at jbjs.org.
Operative Versus Nonoperative Treatment for Adult
Symptomatic Lumbar Scoliosis
Michael P. Kelly, MD, MSc, Jon D. Lurie, MD, Elizabeth L. Yanik, PhD, ScM, Christopher I. Shaffrey, MD,
Christine R. Baldus, RN, MHS, Oheneba Boachie-Adjei, MD, Jacob M. Buchowski, MD, Leah Y. Carreon, MD, MSc,
Charles H. Crawford III, MD, Charles Edwards II, MD, Thomas J. Errico, MD, Steven D. Glassman, MD, Munish C. Gupta, MD,
Lawrence G. Lenke, MD, Stephen J. Lewis, MD, MSc, FRCSC, Han Jo Kim, MD, Tyler Koski, MD, Stefan Parent, MD, PhD,
Frank J. Schwab, MD, Justin S. Smith, MD, PhD, Lukas P. Zebala, MD, and Keith H. Bridwell, MD
Background: The effectiveness of operative compared with nonoperative treatment at initial presentation (no prior fusion)
for adult lumbar scoliosis has not, to our knowledge, been evaluated in controlled trials. The goals of this study were to
evaluate the effects of operative and nonoperative treatment and to assess the beneﬁts of these treatments to help treating
physicians determine whether patients are better managed operatively or nonoperatively.
Methods: Patients with adult symptomatic lumbar scoliosis (aged 40 to 80 years, with a coronal Cobb anglemeasurement of
‡30 and an Oswestry Disability Index [ODI] score of ‡20 or Scoliosis Research Society [SRS]-22 score of £4.0) from 9 North
American centers were enrolled in concurrent randomized or observational cohorts to evaluate operative versus nonoperative
treatment. The primary outcomeswere differences in themean change frombaseline in the SRS-22 subscore andODI at 2-year
follow-up. For the randomized cohort, the initial sample-size calculation estimated that 41 patients per group (82 total) would
provide80%powerwith alpha equal to 0.05, anticipating 10% loss to follow-up and20%nonadherence in the nonoperative arm.
However, an interim sample-size calculation estimated that 18 patients per group would be sufﬁcient.
Results: Sixty-three patients were enrolled in the randomized cohort: 30 in the operative group and 33 in the nonoperative
group. Two hundred and twenty-three patients were enrolled in the observational cohort: 112 in the operative group and 111 in
the nonoperative group. The intention-to-treat analysis of the randomized cohort found that, at 2 years of follow-up, outcomes
did not differ between the groups. Nonadherencewas high in the randomized cohort (64% nonoperative-to-operative crossover).
In the as-treated analysis of the randomized cohort, operative treatment was associated with greater improvement at the 2-year
follow-up in the SRS-22 subscore (adjusted mean difference, 0.7 [95% conﬁdence interval (CI), 0.5 to 1.0]) and in the ODI
(adjustedmean difference,216 [95% CI,222 to210]) (p < 0.001 for both). Surgery was also superior to nonoperative care in
the observational cohort at 2 years after treatment on the basis of SRS-22 subscore and ODI outcomes (p < 0.001). In an
overall responder analysis, more operative patients achieved improvement meeting or exceeding the minimal clinically
important difference (MCID) in the SRS-22 subscore (85.7% versus 38.7%; p < 0.001) and the ODI (77.4% versus 38.3%;
p < 0.001). Thirty-four revision surgeries were performed in 24 (14%) of the operative patients.
Conclusions: On the basis of as-treated and MCID analyses, if a patient with adult symptomatic lumbar scoliosis
is satisﬁed with current spine-related health, nonoperative treatment is advised, with the understanding that improvement
is unlikely. If a patient is not satisﬁed with current spine health and expects improvement, surgery is preferred.
Level of Evidence: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.
Disclosure: Funding was exclusively from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the U.S. National Institutes of
Health (R01AR055176). On the Disclosure of Potential Conﬂicts of Interest forms, which are provided with the online version of the article, one or more
of the authors checked “yes” to indicate that the author had a relevant ﬁnancial relationship in the biomedical arena outside the submitted work; “yes” to
indicate that the author had a patent and/or copyright, planned, pending, or issued, broadly relevant to this work; and “yes” to indicate that the author had
other relationships or activities that could be perceived to inﬂuence, or have the potential to inﬂuence, what was written in this work (http://links.lww.
com/JBJS/F140).
A data-sharing statement is provided with the online version of the article (http://links.lww.com/JBJS/F141).
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dult spinal deformity affects 15% of the U.S. popu-
lation1,2. Adult symptomatic lumbar scoliosis is
the most common form of adult spinal deformity
and is associated with disability similar to that of other
chronic conditions such as diabetes mellitus and rheuma-
toid arthritis3.
Surgical treatment of lumbar scoliosis is costly, with re-
admissions and revision surgeries4,5. Nonoperative treatments
may not improve health-related quality of life6,7. Little data exist
to determine the efﬁcacy of operative versus nonoperative
care8-10.
We present results from a multicenter trial with ran-
domized and observational cohorts, ASLS-1 (Adult Sympto-
matic Lumbar Scoliosis-1), comparing the effects of operative
and nonoperative treatment at primary presentation (no prior
fusion) on health-related quality of life among patients with
adult symptomatic lumbar scoliosis and assessing the beneﬁts
of these treatments.
Materials and Methods
This study was registered at ClinicalTrials.gov (numberNCT00854828).
Fig. 1
Flow of participants from screening and enrollment through 2-year follow-up (F/U) in the randomized and observational cohorts. Follow-up time points
indicate the time since ﬁrst treatment occurred. The numbers of those who withdrew, died, or underwent surgery are cumulative across follow-up time
points. Individuals who opted for surgery outside of the study were counted as patients who underwent surgery and as withdrawals at the time of surgery.
Withdrawal counts do not include deaths.
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TABLE I Baseline Data
Baseline
Baseline/Enrollment Variable








(N = 111) P Value
Age* (yr) 63 (53, 66) 63 (57, 69) 0.47 59 (53, 64) 61 (54, 69) 0.06
Female sex (no. [%]) 26 (86.7) 29 (87.9) 0.89 102 (91.1) 101 (91.0) 0.98
Race (no. [%]) 0.60 0.08
White 28 (93.3) 32 (97.0) 108 (96.4) 100 (90.1)
Black 2 (6.7) 1 (3.0) 2 (1.8) 9 (8.1)
Other 0 (0) 0 (0) 2 (1.8) 2 (1.8)
Ethnicity (no. [%]) 1.00 0.25
Hispanic 0 (0) 0 (0) 3 (2.8) 0 (0)
Non-Hispanic 29 (100) 31 (100) 106 (97.3) 104 (100)
Did not report 1 2 3 7
Education (no. [%]) 0.64 0.14
Less than high school 1 (3.3) 4 (12.1) 1 (0.9) 3 (2.7)
High school or general
equivalency diploma (GED)
7 (23.3) 5 (15.2) 26 (23.2) 38 (34.2)
Technical or associate
degree
8 (26.7) 11 (33.3) 18 (16.1) 13 (11.7)
Bachelor’s degree 7 (23.3) 6 (18.2) 28 (25.0) 31 (27.9)
Graduate degree 7 (23.3) 7 (21.2) 39 (34.8) 26 (23.4)
Income per yr (no. [%]) 0.63 0.23
<$20,000 1 (4.4) 2 (6.7) 6 (6.5) 8 (8.1)
$20,000-$39,999 1 (4.4) 5 (16.7) 11 (11.8) 14 (14.1)
$40,000-$74,999 9 (39.1) 10 (33.3) 15 (16.1) 26 (26.3)
‡$75,000 12 (52.2) 13 (43.3) 61 (65.6) 51 (51.5)
Did not report 7 3 19 12
Smoking (no. [%]) 0.59 0.93
Current 1 (3.3) 3 (9.1) 6 (5.4) 7 (6.3)
Former 11 (36.7) 13 (39.4) 31 (27.7) 32 (28.8)
Never 18 (60.0) 17 (51.5) 75 (67.0) 72 (64.9)




None/does not apply 11 (36.7) 11 (33.3) 42 (37.5) 48 (43.2)
T-score 21 to 21.5 12 (40.0) 11 (33.3) 32 (28.6) 20 (18.0)
T-score 21.6 to 22.4 6 (20.0) 7 (21.2) 29 (25.9) 33 (29.7)
T-score 22.5 or worse (or
vertebral compression
fracture)
1 (3.3) 4 (12.1) 9 (8.0) 10 (9.0)
Hypertension (uncontrolled or
requiring medications) (no. [%])
0.71 0.95
No 16 (53.3) 17 (51.5) 70 (62.5) 68 (61.3)
Yes, controlled with diet/
exercise
1 (3.3) 0 (0) 4 (3.6) 4 (3.6)
Yes, controlled with
medication
13 (43.3) 16 (48.5) 37 (33.0) 39 (35.1)
Yes, poorly controlled with
medication
0 (0) 0 (0) 1 (0.9) 0 (0)
continued
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Trial Design
ASLS-1 was conducted at 9 centers in North America and in-
cluded randomized and observational cohorts of patients11. All
sites individually obtained institutional review board approval.
Trial Oversight
An independent data safety monitoring board and safety ofﬁcer
evaluated safety and the completeness of data collection bian-
nually. Investigators collected the data and approved the ﬁnal
submission.
Patient Population
Eligible were patients 40 to 80 years of age who had adult
symptomatic lumbar scoliosis, deﬁned as a lumbar curve with
a coronal Cobb angle measurement of ‡30 and an Oswestry












(N = 111) P Value
Diabetes (uncontrolled or
requiring medications) (no. [%])
0.24 0.39
No 29 (96.7) 29 (87.9) 108 (96.4) 106 (95.5)
Yes, controlled with diet 0 (0) 0 (0) 0 (0) 2 (1.8)
Yes, controlled with oral
hypoglycemics
0 (0) 3 (9.1) 4 (3.6) 2 (1.8)
Yes, insulin-dependent 1 (3.3) 1 (3.0) 0 (0) 1 (0.9)
Depression/anxiety/
psychiatric disorder (no. [%])
11 (36.7) 9 (27.3) 0.42 35 (31.3) 22 (19.8) 0.05
Duration of back symptoms*
(mo)
36 (0, 80) 96 (12, 240) 0.08 12 (0, 60) 24 (2, 120) 0.07
Duration of leg symptoms* (mo) 3 (0, 48) 0 (0, 12) 0.53 0 (0, 12) 0 (0, 12) 0.93
Lumbar Cobb angle* () 55 (47, 62) 48 (37, 63) 0.25 57 (45, 69) 48 (39, 57) <0.001
Lumbar lordosis (T12-
sacrum)* ()
232 (256, 222) 238 (247, 220) 0.78 238 (249, 228) 245 (255, 232) 0.05
Sagittal balance absolute
value* † (mm)
27 (17, 57) 34 (21, 70) 0.23 26 (11, 56) 33 (16, 55) 0.33
Coronal balance absolute
value* † (mm)
13 (6, 30) 23 (14, 38) 0.08 19 (9, 35) 14 (8, 26) 0.05
Pelvic incidence-lumbar
lordosis mismatch* ‡ ()
14 (2, 32) 25 (15, 34) 0.11 15 (5, 30) 13 (1, 28) 0.10
No. of stenosis levels* 1 (0, 3) 0 (0, 1) 0.05 1 (0, 2) 0 (0, 1) 0.003
Listhesis (no. [%]) 27 (90.0) 28 (84.9) 0.71 104 (92.9) 95 (85.6) 0.08
Baseline patient-reported
outcomes* §
SRS-22 subscore 3.2 (2.7, 3.5) 2.9 (2.7, 3.5)# 0.41 3.1 (2.7, 3.5) 3.4 (3.0, 3.7)# 0.003
SRS-22 pain 3 (2.6, 3.4) 2.8 (2.2, 3.2) 0.10 2.8 (2.2, 3.3) 3.0 (2.6, 3.6) 0.008
SRS-22 function 3.2 (2.8, 3.8) 3.0 (2.8, 3.6) 0.70 3.2 (2.6, 3.8) 3.4 (3.0, 3.8) 0.008
SRS-22 self-image 2.8 (2.3, 3.3) 2.8 (2.5, 3.2) 1.00 2.8 (2.2, 3.3) 3.0 (2.7, 3.5) <0.001
SRS-22 mental health 3.8 (3, 4.4) 4.0 (3.2, 4.0) 0.77 3.8 (3.2, 4.2) 3.8 (3.2, 4.4) 0.83
SRS-22 satisfaction 2.5 (2, 3) 3.0 (2.5, 4.0) 0.11 3.0 (2.0, 3.0) 3.0 (2.5, 3.5) 0.06
ODI score 34 (24, 46) 46 (28, 54)** 0.07 37 (26, 48) 32 (22, 40)** 0.008
*The values are given as the median, with the interquartile range in parentheses. †Information on sagittal and coronal balance was missing for 1 patient
assigned to operative treatment in the randomized cohort because baseline images were done at an outside facility and did not include scales to permit
linear measurements.‡Information on pelvic incidence-lumbar lordosis mismatch was missing for 17 patients because femoral heads were not visible on
radiographs. This included 3 patients assigned to nonoperative treatment in the randomized cohort. Among the observational cohort patients, 7 in the
operative group and 7 in the nonoperative group did not have pelvic incidence-lumbar lordosis mismatch information. §SRS scale: 1 to 5, with 5 indicating
no pathology; and ODI scale: 0 to 100, with 0 indicating no pathology. #Nonoperative randomized versus nonoperative observational, p = 0.01.
**Nonoperative randomized versus nonoperative observational, p = 0.002.
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Society (SRS)-22 score of £4.0 in the domains of pain, func-
tion, and/or self-image, who presented to a spinal-deformity
surgeon. It is uncommon to see patients <40 years of age with
degenerative changes. Patients >80 years of age are frequently
too frail to be considered surgical candidates. Enrolled
patients did not have prior spinal fusion or multilevel
decompression surgery. A past, single-level laminotomy for
disc herniation was not an exclusion. The SRS-22 is a disease-
speciﬁc, validated instrument for spinal deformity, and the ODI
is a disease-speciﬁc instrument for lumbar spine disability. The
SRS-22 consists of 5 domains, the subscore being the average,
excluding satisfaction.
Patients, all deemed surgical candidates by the treating
physician, were offered enrollment. The patients in the ran-
domized cohort received assignment through permuted block
randomization, with block sizes of 4, 6, and 8, which were
stratiﬁed by site, age group (40 to 59 and 60 to 80 years), sex,
and Cobb angle-based severity (30 to 54, 55 to 100).
Patients in the concurrent observational cohort who declined
randomization chose which treatment to receive (operative or
nonoperative). Enrollment in both cohorts began in April
2010, and was closed in July 2014.
Trial Interventions
Surgical procedures included instrumented spinal fusion for
all patients, with laminectomies for symptomatic spinal
stenosis. Surgical goals were 30% to 50% correction in the
coronal plane and normalization of the sagittal plane. At
each site, a physician was prespeciﬁed to direct nonoperative
care, which included physical therapy (muscle strengthening
and aerobic conditioning), injections, oral medications, and
complementary resources. The care was standardized across
TABLE III Characteristics of Patients Assigned to Nonoperative Treatment in the Randomized Cohort, by Adherence, and Predictors of
Crossovers
Characteristic
Nonoperative Treatment Group in the Randomized Cohort at Baseline














24.5 (15.5, 34.5) 26.5 (8, 34) 1.00 18 (22, 32) 31 (18, 45) 0.08
SRS-22 subscore 3.1 (2.7, 3.5) 2.9 (2.6, 3.2) 0.29 3.6 (3.3, 3.8) 2.8 (2.6, 3.1) 0.01
ODI score 44 (24, 50) 50 (46, 60) 0.05 22 (15, 40) 48 (44, 54) 0.01
At 6 mo — — —
SRS-22 subscore 3.5 (3.3, 4.0) 2.6 (2.1, 3.2) 0.004
Change in SRS-22
subscore over ﬁrst 6 mo
0 (20.2, 0.2) 20.1 (20.3, 0) 0.20
ODI score 27 (11, 33) 54 (44, 62) <0.001
Change in ODI score over
ﬁrst 6 mo
27 (211, 3) 5 (22, 16) 0.04
*The values are given as the median, with the interquartile range in parentheses.†Wilcoxon rank-sum tests for continuous variables.‡Information
on pelvic incidence-lumbar lordosis mismatch was missing for 2 patients because femoral heads were not visible on radiographs.
TABLE II Early and Late Crossover Proportions Among Patients Originally in the Nonoperative Treatment Arms
Cohort









Randomized 7 7/33 (21.2%) <0.001 14 14/26 (53.8%) <0.001
Observational 3 3/111 (2.7%) 11 11/104 (10.6%)
*Denominators represent the number of remaining patients who had not crossed over or withdrawn in the ﬁrst 6 months. (In the randomized
cohort, 7 patients crossed over in ﬁrst 6 months. In the observational cohort, 3 patients crossed over and 4 patients withdrew in the ﬁrst 6
months).
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centers. The physical therapy was tailored to each patient,
not protocolized. However, back pain was treated with phys-
ical therapy, facet injections, and nonsteroidal medications
(NSAIDs [nonsteroidal anti-inﬂammatory drugs]) with inter-
mittent opioids. Leg painwas treated with activity modiﬁcation,
gabapentin, and nerve-root injections as well as with physical
therapy. “Usual care” was employed for patients treated both
operatively and nonoperatively to make results more general-
izable, as advocated by Dawson et al.12 andWeinstein et al.13, and
to reduce nonoperative care sought outside the study by offering
patients all available nonoperative treatment options.
Trial Outcomes
The primary outcomes were differences in the mean change
from baseline to the 2-year follow-up between the operative
and nonoperative groups (treatment effect) in the SRS-22
subscore and in the ODI. Assessments were made at enroll-
ment and at 3-month intervals until 2 years. For the ran-
domized cohort, enrollment data served as the baseline for all
patients in the intention-to-treat analysis. In the as-treated
analysis, enrollment data served as the baseline for patients
in the nonoperative cohort while baseline data for surgical
patients were updated if necessary within 4 months of surgery.
Speciﬁed radiographic parameters were based on 36-inch
(91.4 cm) standing radiographs for operatively and non-
operatively treated patients, obtained at enrollment and 2 years
post-treatment. Adverse events and changes in comorbidities
were recorded by study coordinators at each site, with quality
analysis by a single, centralized study coordinator. Serious
adverse events (SAEs) were deﬁned as death, a life-threatening
event, hospitalization, a new disability, and/or any unexpected
related event.
Statistical Analysis
For the randomized cohort, an a priori sample size of 82
patients (41 per treatment arm) was estimated to provide 80%
power, anticipating 10% loss to follow-up and 20% crossover
from nonoperative to operative intervention. An interim
Fig. 2-A
Figs. 2-A through 2-F Comparison of operative versus nonoperative treatment for patient-reported primary outcomes from the intention-to-treat and as-
treated analyses of the randomized cohort and the as-treated analyses of the observational cohort. Graphs and tables show the intention-to-treat analyses
of the randomized cohort for the Scoliosis Research Society (SRS)-22 subscore (Fig. 2-A) and the Oswestry Disability Index (ODI) score (Fig. 2-B); the as-
treated analyses of the randomized cohort for theSRS-22 subscore (Fig. 2-C) and theODI score (Fig. 2-D); and the as-treated analyses of the observational
cohort for theSRS-22 subscore (Fig. 2-E) and theODI score (Fig. 2-F). The observedmean baseline scores (0months) and scores based on estimates from
the generalized linear mixed models (all other follow-up time points) are provided. Error bars indicate the 95% conﬁdence interval. The SRS-22 subscore
ranges from 1 to 5, with a higher score indicating a better outcome. The ODI score ranges from 0 to 100, with a higher score indicating greater disability.
Estimated changes from baseline in both study groups (operative and nonoperative) may not add/subtract exactly due to rounding of all data points and
differences between modeled score estimates versus observed scores.
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sample-size estimation was performed on 1-year outcomes for
this study for 26 randomized patients using bootstrapping for
1,000 samples and found that 18 patients per group (36 total
randomized), assuming an SRS-22 subscore treatment effect
of ‡0.714, would provide 80% power with alpha equal to
0.05. Enrollment in the randomized cohort was stopped in
2014, with 63 patients, to allow 2-year follow-up by the end
of 2016.
Baseline characteristics were compared between the
groups using the chi-square test for categorical variables (or
the Fisher exact test when there were counts of <5) and
Wilcoxon rank-sum test for continuous variables. Baseline
health-related quality-of-life scores and patient characteristics
associated with treatment (p < 0.05) were also compared
between patients who adhered to the initial treatment assign-
ment and patients who crossed to the other treatment arm.
Counts and SAE rates were described for each treatment arm
of the cohorts. The noninferiority margin was deﬁned as the
minimum detectable measurement difference (SRS-22: 0.4;
ODI: 7.0)14.
An intention-to-treat analysis was performed for the
randomized cohort using generalized linear mixed models
(GLMMs) controlling for baseline outcome-measure scores.
As-treated analyses were performed with similar models
evaluating treatment as a time-varying covariate for both the
randomized cohort and observational cohort. To account for
potential confounding, baseline characteristics deﬁned a
priori as important outcome predictors or identiﬁed as
associated with treatment in initial analyses were considered
for inclusion in the models. Interpretation of this study as
pragmatic in approach is preferred; pragmatic trials offer
insight into the effectiveness of interventions, as they most
closely approximate clinical practice, offering high external
validity15,16.
Rates of missing data were compared between groups,
and patient-level comparisons were made using the Wilcoxon
rank-sum test for continuous variables and Fisher exact test
for categorical data. The GLMM used all information avail-
able, with missing data treated as missing at random.
To determine whether changes in health-related quality-
of-life measures were clinically meaningful, responder analyses
were performed, evaluating the time to a minimal clinically
important difference (MCID) for the primary outcomes (MCID
for ODI = 10.9, and MCID for SRS-22 subscore = 0.43)17,18
among patients adherent to initial treatment, out to 2 years.
Follow-up time started at study entry and was censored at the
ﬁrst of: study withdrawal, death, crossover, or last follow-up
visit. Patient data were included up to the point of crossover for
those who were not adherent to their treatment assignment/
selection. Multivariable Cox regression was used to evaluate
associations between treatment and MCID achievement while
accounting for baseline characteristics. MCID analyses were
Fig. 2-B
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performed for the randomized cohort and for the combined
randomized and observational cohorts.
All statistical tests were 2-sided, and signiﬁcance was
determined on the basis of an alpha of 0.05. Secondary analyses
were exploratory, and no corrections for multiple comparisons
were made.
Results
Two hundred and eighty-six of 582 eligible patients wereenrolled: 63 in the randomized cohort and 223 in the
observational cohort (Fig. 1). As noted above, enrollment in the
randomized cohort was stopped in 2014 with 63 patients to
allow 2-year follow-up by the end of 2016. Two hundred and
ﬁfty-six (90%) completed exact 2-year follow-up. There were 12
withdrawals (4.2% of 286), including 1 death.
Treatment
In the randomized cohort, 33 patients were assigned to non-
operative care and 30, to operative care. Of those assigned to
operative care, 6 (20%) crossed from operative to nonoperative
care. Of those assigned to nonoperative care, 15 (45%) un-
derwent surgery by 1 year, and 6 (18%) underwent surgery
between 1 and 2 years (Fig. 1). Among those with 2-year
follow-up, 45 patients had been treated operatively and 13
patients, nonoperatively.
In the observational cohort, 111 chose nonoperative care
and 112 chose surgery. Of those who opted for nonoperative
care, 14 (13%) underwent surgery by 2 years. No patient in the
group that chose operative treatment crossed over to nonop-
erative treatment, and thus, the overall crossover rate for the
observational cohort was 6.3% (14 of 223) (Fig. 1). Among
those with 2-year follow-up, 118 patients had been treated
operatively and 80 patients, nonoperatively.
Patient Characteristics
The randomized groups did not differ signiﬁcantly with re-
spect to baseline characteristics (Table I). Adjusted models
(for as-treated analyses) accounted for baseline age, body mass
index, psychiatric diagnosis, lumbar Cobb angle, lumbar lor-
dosis, stenosis levels, education, osteoporosis, numerical rating
scale (NRS) for back pain, Short Form (SF)-12 physical com-
ponent summary (PCS) score, SRS-22 subscore, and ODI.





































0 0.00 0 0.00 0 0 0.00 0 0.00 0 —
Pulmonary 1 1.18 10 3.98 11 1 1.11 2 0.51 3 0.11
Gastrointestinal 1 1.18 5 1.99 6 1 1.11 7 1.77 8 0.32
Cancer 0 0.00 2 0.80 2 1 1.11 2 0.51 3 0.47
Cardiovascular 1 1.18 3 1.19 4 0 0.00 4 1.01 4 0.72
Circulatory 2 2.35 2 0.80 4 2 2.22 0 0.00 2 0.61
Genitourinary 0 0.00 6 2.39 6 0 0.00 2 0.51 2 0.30
Death 1 1.18 0 0.00 1 0 0.00 0 0.00 0 1.00
Misc. 2 2.35 11 4.38 13 0 0.00 4 1.01 4 0.10
Total 23 27.03 91 36.22 114 9 9.99 38 9.62 47 <0.001
*Incidence rates are per 100 person-years. †From Poisson models comparing SAE incidence rates between all follow-up time after
operative treatment and all follow-up time during nonoperative treatment. Exact tests were used when 0 counts were observed. ‡ASLS =
adult symptomatic lumbar scoliosis. §Four major deﬁcits (ASIA C); 13 minor deﬁcits (ASIA D). #Non-spine-related (thalamic stroke and
traumatic brain injury).
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Adjustments address nonoperative observational patients’ pre-
sentation with somewhat less pathology (e.g., median SRS-22
subscore, 3.4; median ODI, 32) than operative patients (e.g.,
median SRS-22 subscore, 3.1; median ODI, 37).
Early and late crossover proportions among patients
originally in the nonoperative treatment arms are shown in
Table II.
In the randomized cohort, the characteristics of pa-
tients who crossed over to operative treatment within 6
months of enrollment (7 patients) did not differ from those
of patients who did not cross over (“adherent” patients).
Patients who crossed over to operative treatment after 6
months (14 patients) had signiﬁcantly worse SRS-22 sub-
score values, and worse ODI scores as well as worsening in
TABLE V Details of Serious Adverse Events (SAEs) Requiring Revision Spine Surgery
As-Treated Operative
SAE
Randomized Cohort Observational Cohort
Total
No. Incidence Rate* No. Incidence Rate* No.
During index procedure hospitalization 0 6 6
Malpositioned screw (or minor neurological deﬁcit) 0 1
Major neurological deﬁcit 0 2
Wound issues 0 3
Within 90 days after index procedure 1 8.70 5 15.69 6
Proximal junctional failure 0 0.00 3 9.41
Major neurological deﬁcit 1 8.70 0 0.00
Wound issues 0 0.00 1 3.14
Cerebrospinal ﬂuid leak 0 0.00 1 3.14
91 days-1 yr after index procedure 3 8.99 9 9.54 12
Malpositioned screw (or minor neurological deﬁcit) 0 0.00 2 2.12
Major neurological deﬁcit 1 3.00 0 0.00
Proximal junctional failure 0 0.00 3 3.18
Implant failure/pseudarthrosis 0 0.00 3 3.18
Other implant issues 2 6.00 1 1.06
1-2 yr after index procedure 3 7.46 7 5.60 10
Proximal junctional failure 2 4.97 1 0.80
Implant failure/pseudarthrosis 1 2.49 6 4.80
Total 7 8.23 27 10.75 34
*Incidence rates are per 100 person-years.
TABLE VI Effect of Related Serious Adverse Events (SAEs) on Primary Outcomes Among Operative Patients, from the Combined
(Randomized and Observational) As-Treated Analysis*
2 Yr
Mean Change from Baseline (SE)
SAE No SAE Difference in Mean Change (95% CI) P Value
SRS-22 subscore 0.52 (0.08) 0.79 (0.06) 20.27 (20.45, 20.09) 0.004
ODI score 211.59 (2.07) 217.34 (1.35) 5.76 (0.87, 10.64) 0.02
*SE = standard error, and CI = conﬁdence interval. Estimates for the SRS-22 subscore and ODI score are from generalized linear mixed-effects
models accounting for the correlation among repeated measures using a heterogeneous autoregressive covariance matrix. SAE was considered a
time-varying covariate, for which all outcomesmeasuredafter anSAEoccurrencewere categorizedasbeing for anSAE.Resultswere adjusted for the
baseline value of each outcome. All models were also adjusted for the following baseline characteristics: age, body mass index, depression/
anxiety/psychiatric disorder, lumbar Cobb angle, lumbar lordosis, stenosis levels, education, osteoporosis, SRS-22 subscore, ODI, NRS for back
pain, and SF-12 PCS.
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ODI at 6 months compared with the adherent randomized
patients (Table III).
Missing Data
Rates of missing data were low for both cohorts and did not
differ between the groups at 2 years: 90% of the operative and
94% of the nonoperative patients in the randomized cohort
attended their 2-year visit, and 93% of the operative and 85%
of the nonoperative patients in the observational cohort at-
tended their 2-year visit (Fig. 1).
Nonoperative Treatment
Nonoperative treatments did not differ between the random-
ized cohort and the observational cohort and included NSAIDs
or gabapentin (76%), opioids (52%), physical therapy (57%),
and spinal injections (34%).
Operative Treatment
Of patients treated operatively, 3 patients opted for surgery
outside the trial when they crossed over from nonoperative
treatment and were considered withdrawn from the trial.
On average, the operative time was 386minutes, 10.9 levels were
fused, and estimated blood loss was 2,047 mL in 171 patients.
Primary Outcomes
Intention-to-Treat
In the intention-to-treat analysis of the randomized cohort,
operative treatment was associated with greater improvement
TABLE VII Comparison of Primary Outcomes for Operative Patients with and without a Serious Adverse Event (SAE) and Nonoperative
Patients, from the As-Treated Analysis Combining Randomized and Observational Cohorts*
2 Yr
Mean Change from Baseline (SE) Difference in Mean Change (95% CI) P Value
SRS -22 subscore Nonoperative 0.11 (0.05) Ref.
Operative with an SAE 0.51 (0.07) 0.39 (0.22, 0.56) <0.001
Operative with no SAE 0.75 (0.05) 0.64 (0.50, 0.77) <0.001
ODI score Nonoperative 21.57 (1.26) Ref.
Operative with an SAE 210.51 (1.91) 28.94 (213.34, 24.54) <0.001
Operative with no SAE 215.79 (1.29) 214.22 (217.59, 210.85) <0.001
*SE = standard error, and CI = conﬁdence interval. Estimates for the SRS-22 subscore and ODI score are from generalized linear mixed-effects
models accounting for the correlation among repeated measures using a heterogeneous autoregressive covariance matrix. SAE was considered a
time-varying covariate, for which all outcomesmeasuredafter anSAEoccurrencewere categorizedasbeing for anSAE.Resultswere adjusted for the
baseline value of each outcome. All models were also adjusted for the following baseline characteristics: age, body mass index, depression/
anxiety/psychiatric disorder, lumbar Cobb angle, lumbar lordosis, stenosis levels, education, osteoporosis, SRS-22 subscore, ODI, NRS for back
pain, and SF-12 PCS.




Difference At 2 Yr† (no. [%])
Odds Ratio (95% CI)‡ P ValueOperative Nonoperative
Lumbar Cobb angle () 134 (99%) 23 (25%) 349.62 (65.73, 1,859.68) <0.001
Coronal balance (absolute value) (mm) 39 (29%) 15 (16%) 1.59 (0.71, 3.58) 0.26
Lumbar lordosis (T12-sacrum) () 95 (70%) 12 (13%) 24.60 (10.15, 59.62) <0.001
Sagittal balance (absolute value) (mm) 53 (40%) 16 (18%) 4.81 (1.91, 12.10) <0.001
Pelvic incidence-lumbar lordosis mismatch () 91 (70%) 12 (14%) 26.67 (10.29, 69.12) <0.001
*Reproducible radiographic differences were deﬁned as a difference of at least 5 for the lumbarCobb angle, lumbar lordosis, and pelvic incidence-
lumbar lordosis mismatch or a difference of 10 mm for coronal and sagittal balance. Odds ratios comparing the odds of achieving a reproducible
radiographic difference in operative versus nonoperative patients were estimated using logistic regression. †For radiographic analyses, patients
were only included if they had available results from a radiograph within 1 year prior to the start of intervention and a follow-up radiograph between
1 and 3 years after the start of intervention. There were 136 operative and 92 nonoperative patients who met these criteria. Information was not
available at both baseline and 2 years regarding coronal balance for 2 operative patients, regarding sagittal balance for 2 operative patients and
1 nonoperative patient, and regarding pelvic incidence-lumbar lordosis mismatch for 6 operative and 9 nonoperative patients. ‡CI = conﬁdence
interval.
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compared with nonoperative treatment at the 1-year follow-up
with respect to both the SRS-22 subscore (unadjusted mean
difference, 0.5 [95% conﬁdence interval (CI), 0.2 to 0.7]) and
ODI (unadjusted mean difference,215 [95% CI,222 to28]).
At the 2-year follow-up, the change from baseline in the SRS-22
subscore (unadjusted mean difference, 0.1 [95% CI, 20.2 to
0.4]) and in the ODI (unadjusted mean difference, 24 [95%
CI, 213 to 4]) did not differ signiﬁcantly between the groups
(Figs. 2-A and 2-B).
As-Treated
In the as-treated analysis of the randomized cohort, operative
treatment was associated with greater improvement (p < 0.001)
compared with nonoperative treatment at 2 years in the SRS-22
subscore (unadjusted mean difference, 0.7 [95% CI, 0.5 to 1.0]);
adjusted mean difference, 0.7 [95% CI, 0.5 to 1.0]) and ODI
(unadjusted mean difference, 215 [95% CI, 222 to 29];
adjusted mean difference,216 [95% CI,222 to210]) (Figs.
2-C and 2-D). Similarly, in the as-treated analysis of the
observational cohort, operative treatment was signiﬁcantly
(p < 0.001) associated with greater improvement in the SRS-
22 subscore and ODI measures at the 2-year follow-up (Figs.
2-E and 2-F). Outcome measures did not differ from enroll-
ment in the nonoperative group at the 2-year follow-up for
either outcome, in both the randomized cohort and obser-
vational cohort; on average, nonoperatively treated patients
did not improve from baseline.
Adverse Events
There were 114 SAEs among the operative patients. Four (3%)
of the nonoperative patients sustained SAEs related to NSAID
use. New neurological deﬁcits occurred in 9.9% of the opera-
tive patients (17 of 171); 4 were major (American Spinal Injury
Association [ASIA] C classiﬁcation). One patient with a major
deﬁcit died; 2 others improved to ASIA D. There were 34
revision surgeries performed in 24 (14%) of the patients. The
most common reasons for reoperation were failure to achieve
fusion (pseudarthrosis) (n = 10) and proximal junctional fail-
ure (n = 9). Patients sustaining a surgery-related SAE experi-
enced less improvement in outcome measures than did those
without an SAE but did still improve compared with nonop-
erative patients (Tables IV through VII).
Radiographic Measurements
In a combined as-treated analysis of data from 2 years post-
treatment, radiographic deterioration was uncommon with
nonoperative care. Most operative patients achieved a repro-
ducible radiographic improvement for the lumbar Cobb angle
and sagittal parameters (Table VIII).
Responder Analysis
In the randomized cohort responder analysis, more operative
than nonoperative patients achieved improvements meeting or
exceeding the MCID for both primary outcome measures, the
SRS-22 subscore (80.8% versus 17.0%; p < 0.001) and ODI
(80.8% versus 40.1%; p = 0.004) at 2 years. The combined
cohort results were consistent, with more operative patients
achieving improvement meeting or achieving the MCID in the
SRS-22 subscore (85.7% versus 38.7%; p < 0.001) and ODI
(77.4% versus 38.3%; p < 0.001).
Discussion
The as-treated analyses of the randomized and observationalcohorts found beneﬁts for operative over nonoperative
treatment when controlling for potential confounders (could
not control for unmeasured variables or resolve patient or
surgeon selection bias), with improvements in the SRS-22
subscore and ODI at the 2-year follow-up. We also performed a
responder analysis, which showed that a minority of patients in
the nonoperative group achieved a minimal clinically impor-
tant improvement, while >80% achieved this improvement
in the group randomized to surgery and in the combined
population.
For the randomized cohort, when studied as assigned
(intention-to-treat), we found that surgery was more effec-
tive than nonoperative treatment at the 1-year follow-up, but
at the 2-year follow-up, average changes in the SRS-22
subscore and ODI did not differ signiﬁcantly between the
treatment groups. Randomization was successful in dis-
tributing baseline covariates; however, there was substantial
nonadherence to treatment assignment, particularly in the
group randomized to nonoperative treatment, where we
observed substantial resistance to assigned treatment. The
crossover rate at 2 years was in excess of 50%, mostly non-
operative to operative, with similar numbers of patients
treated operatively in each group at 2 years. Crossover rates
this high would require an unachievable sample size to reach
signiﬁcance in an intention-to-treat analysis. Therefore, our
study conclusions are drawn mainly from the 2-year as-
treated (randomized cohort and observational cohort) and
MCID analyses.
In the as-treated analyses of the randomized cohort
and the observational cohort, nonoperative treatment was
not found to be associated with a worsening of quality of
life for treatment-adherent patients, on the basis of SRS-22
subscore and ODI measures. Conclusions regarding speciﬁc
nonoperative therapies are limited because interventions
were tailored to patients with back and leg pain treated
differently. The muscle-strengthening and aerobic condi-
tioning (physical therapy) treatments were not protocolized.
This decision was made because there is no accepted “usual
care” and we are aware of no comparative study to have
deﬁned the appropriate physical therapy for this class of
patients. Our intent was to provide “usual care” to both op-
erative and nonoperative patients so that our results would be
generalizable12.
Complications related to surgery were substantial, with a
high number of SAEs in the operative cohort. One patient who
sustained a major neurological deﬁcit died as a result of sur-
gery. This devastating complication must be considered when
discussing the potential beneﬁts of surgery as it is not appre-
ciated in the inferential analysis. Despite the high frequency of
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surgery-related SAEs, these patients did improve with respect
to primary outcome measures, although less so than patients
without SAEs.
Few reports have compared operative and nonopera-
tive care in adult spinal deformity8-10. The European Spine
Study Group (ESSG), the International Spine Study Group
(ISSG), and the Spinal Deformity Study Group (SDSG)
maintain registries of patients with adult spinal deformity,
of which those with lumbar scoliosis are a subset, and have
contributed the largest series. As with most registries, these
reports are limited by their heterogeneity, nonconsecutive
enrollment, and substantial loss to follow-up. In particular, the
ISSG and ESSG studies included revision adult deformity, a
diagnosis distinctly different from primary (no prior fusion) adult
lumbar scoliosis19. Loss to follow-up of the nonoperative patients
in these cohorts approached 50%. We focused on primary
treatment for adult symptomatic lumbar scoliosis and report
90% follow-up at 2 years after enrollment.
There were important limitations to this study. First was
the nonprotocolization of physical therapy for the nonopera-
tively treated patients. Second was the difﬁculty in formulating
conclusions for the randomized cohort when analyzed as as-
signed (intention-to-treat) due to limited enrollment numbers
and high crossover by 2 years. Third, there was the potential for
selection, indication, and expertise bias to have inﬂuenced
results. The ﬁndings may not be applicable to all clinical con-
texts outside the 9 centers in North America in which the work
was conducted.
In conclusion, lower enrollment than anticipated and
a high rate of crossovers in the randomized cohort limit
conclusions and interpretation of the intention-to-treat anal-
ysis. The as-treated analyses of the randomized cohort and
concomitant observational cohort found surgery to be superior
to nonoperative care at the 2-year follow-up, as did the MCID
responder analyses of cohorts. Within the limitations of those
analyses, we recommend nonoperative treatment for patients
content with current spine-related health with the under-
standing that improvement is unlikely. If a patient is not sat-
isﬁed with current spine-related health and has an expectation
of improvement, surgery is preferred and is likely to provide
improvement, although complications, including unplanned
reoperation and neurological deﬁcits, are common. If a pa-
tient starts with nonoperative treatment and is subsequently
dissatisﬁed or spine health deteriorates with time, surgery
may then be considered with an expectation of beneﬁt from
surgery. n
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